MapLight Therapeutics Announces Positive Phase 2 Schizophrenia Data
SAN FRANCISCO and BOSTON, July 27, 2026 MapLight Therapeutics announced positive topline results from its Phase 2 ZEPHYR clinical...
schizophrenia
Advertisement
LB Pharmaceuticals Accelerates Phase 3 LB-102 Schizophrenia Timeline
New York, July 22, 2026 LB Pharmaceuticals announced that it now expects to report topline results from the pivotal...
TG Therapeutics Launches Phase 2 BRIUMVI Trial
NEW YORK, July 6, 2026 TG Therapeutics, Inc. announced the initiation of a Phase 2 clinical trial evaluating BRIUMVI®...
Newron Reports FDA Progress on Evenamide Phase 3 ENIGMA-TRS 2 Trial
MILAN, Italy, and MORRISTOWN, N.J., July 2, 2026 Newron Pharmaceuticals announced a constructive Type A meeting with the U.S....
BioXcel Reports Positive Phase 3 At-Home Agitation Data
NEW HAVEN, Conn. | May 28, 2026 BioXcel Therapeutics presented new positive data from its Phase 3 SERENITY At-Home...
Advertisements
Teva Advances Schizophrenia Therapy in Europe
TEL AVIV, Israel & PARIS, May 21, 2026 Teva Pharmaceuticals and Medincell have announced that the European Medicines Agency...
Johnson & Johnson Showcases Neuropsychiatry Data at APA 2026
TITUSVILLE, N.J., May 11, 2026 Johnson & Johnson announced the presentation of 18 new and encore abstracts highlighting the...
MapLight Therapeutics Completes Phase 2 CNS Trials Enrollment
SAN FRANCISCO & BOSTON, May 1, 2026 MapLight Therapeutics, Inc. announced the completion of enrollment in its Phase 2...
Nxera Pharma Advances Schizophrenia Drug to Phase 2
TOKYO, Japan and CAMBRIDGE, UK, April 13, 2026 Nxera Pharma Co., Ltd. announced that its partner Neurocrine Biosciences, Inc....
Axsome Acquires Balipodect to Expand CNS Drug Pipeline
NEW YORK, USA — April 1, 2026 Axsome Therapeutics, Inc. has announced the acquisition of exclusive global rights to...
Advertisement
